Celon Pharma S.A. (WSE:CLN)
Poland · Delayed Price · Currency is PLN 16.84
+0.02 (0.12%)
Nov 4, 2026, 3:56 PM CET
Celon Pharma Ratios and Metrics
Market cap in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 907 | 1,096 | 1,425 | 789 | 716 | 1,691 | |
Market Cap Growth | -21.86% | -23.06% | 80.47% | 10.32% | -57.68% | -7.35% |
Enterprise Value | 1,001 | 1,089 | 1,336 | 704 | 578 | 1,487 |
Last Close Price | 16.82 | 20.35 | 26.45 | 15.38 | 13.87 | 32.20 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | 24.47 | 24.15 | 35.84 | 72.92 | 72.92 | 72.92 |
PS Ratio | 3.52 | 4.53 | 6.93 | 3.68 | 3.69 | 8.62 |
PB Ratio | 1.82 | 3.02 | 3.20 | 1.77 | 1.49 | 3.05 |
P/TBV Ratio | 1.91 | 3.15 | 3.26 | 1.83 | 1.56 | 3.21 |
P/FCF Ratio | - | - | - | - | - | 650.25 |
P/OCF Ratio | 33.20 | 45.95 | - | - | - | 38.47 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.88 | 4.50 | 6.50 | 3.28 | 2.98 | 7.59 |
EV/EBITDA Ratio | 90.60 | 107.67 | - | 81.54 | - | 53.42 |
EV/FCF Ratio | - | - | - | - | - | 572.04 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.26 | 0.05 | 0.04 | 0.06 | 0.06 | 0.03 |
Debt / EBITDA Ratio | 3.94 | 0.89 | - | 1.24 | 5.92 | 0.52 |
Debt / FCF Ratio | - | - | - | - | - | 5.74 |
Net Debt / Equity Ratio | 0.19 | 0.00 | -0.13 | -0.20 | -0.29 | -0.38 |
Net Debt / EBITDA Ratio | 3.93 | -0.09 | 4.08 | -10.30 | 53.60 | -7.64 |
Net Debt / FCF Ratio | -1.66 | 0.03 | 1.70 | 2.16 | 3.57 | -81.78 |
Asset Turnover | 0.42 | 0.48 | 0.37 | 0.35 | 0.29 | 0.32 |
Inventory Turnover | 2.33 | 2.41 | 2.23 | 2.06 | 2.15 | 2.32 |
Quick Ratio | 1.38 | 1.14 | 1.90 | 1.89 | 1.70 | 2.95 |
Current Ratio | 1.76 | 1.62 | 2.40 | 2.20 | 2.04 | 3.23 |
Return on Equity (ROE) | 24.17% | -19.63% | -7.73% | -6.08% | -7.60% | -2.58% |
Return on Assets (ROA) | -0.50% | -3.12% | -5.94% | -2.92% | -3.51% | -1.07% |
Return on Invested Capital (ROIC) | -0.63% | -6.68% | -14.24% | -8.12% | -11.09% | -3.17% |
Return on Capital Employed (ROCE) | -0.70% | -6.30% | -11.10% | -5.90% | -7.20% | -1.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 12.12% | -7.24% | -2.42% | -3.56% | -5.49% | -0.69% |
FCF Yield | -6.25% | -2.79% | -2.40% | -5.21% | -5.40% | 0.15% |
Dividend Yield | - | - | - | 0.52% | 0.64% | 0.88% |
Buyback Yield / Dilution | 2.77% | 1.35% | -5.48% | -0.04% | -9.32% | -3.74% |
Total Shareholder Return | 2.77% | 1.35% | -5.48% | 0.47% | -8.68% | -2.87% |